Clinical trials
Completed Phase 2 Papillomavirus Infections trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
38 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 2 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 5 |
| 2007 | 4 |
| 2008 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 38 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| GlaxoSmithKline | 11 |
| Merck Sharp & Dohme LLC | 5 |
| National Cancer Institute (NCI) | 4 |
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 2 |
| Verrica Pharmaceuticals Inc. | 2 |
| AIDS Malignancy Consortium | 1 |
| Beijing Health Guard Biotechnology, Inc | 1 |
| Catalysis SL | 1 |
| Eastern Cooperative Oncology Group | 1 |
| Genexine, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Papillomavirus Infections | 38 |
| Uterine Cervical Neoplasms | 10 |
| Condylomata Acuminata | 7 |
| Squamous Cell Carcinoma of Head and Neck | 4 |
| Uterine Cervical Dysplasia | 4 |
| Virus Diseases | 4 |
| Anus Neoplasms | 3 |
| Precancerous Conditions | 3 |
| Sexually Transmitted Diseases | 3 |
| Vaginal Neoplasms | 3 |
Trials
Showing 1 to 25 of 38. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.